Association of Mirabegron With the Risk of Arrhythmia in Adult Patients 66 Years or Older-A Population-Based Cohort Study.

Tadrous, Mina; Matta, Rano; Greaves, Simon; Herschorn, Sender; Mamdani, Muhammad M; Juurlink, David N; Gomes, Tara · JAMA Intern Med · 2019

prospective_cohort · Level II

Where this comes from

Record sourced from PubMed, PMID 31305875.
Also identified by DOI 10.1001/jamainternmed.2019.2011 and PMC identifier 6632155.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

This population-based cohort study evaluates the risk of cardiac arrhythmia and other cardiovascular events in patients 66 years or older receiving the β3-adrenoceptor agonist mirabegron.

Read the full text

View on PubMed · Publisher (DOI)